搜索结果: 'methocult media formulations for mouse hematopoietic cells serum containing'

文献

Kishimoto RK et al. (APR 2016) Revista brasileira de hematologia e hemoterapia 38 2 113--20

Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells.

BACKGROUND Multiple myeloma is a plasma cell neoplasm with acquired genetic abnormalities of clinical and prognostic importance. Multiple myeloma differs from other hematologic malignancies due to a high fraction of low proliferating malignant plasma cells and the paucity of plasma cells in bone marrow aspiration samples,making cytogenetic analysis a challenge. An abnormal karyotype is found in only one-third of patients with multiple myeloma and interphase fluorescence in situ hybridization is the most useful test for studying the chromosomal abnormalities present in almost 90% of cases. However,it is necessary to study the genetic abnormalities in plasma cells after their identification or selection by morphology,immunophenotyping or sorting. Other challenges are the selection of the most informative FISH panel and determining cut-off levels for FISH probes. This study reports the validation of interphase fluorescence in situ hybridization using CD138 positive cells,according to proposed guidelines published by the European Myeloma Network (EMN) in 2012. METHOD Bone marrow samples from patients with multiple myeloma were used to standardize a panel of five probes [1q amplification,13q14 deletion,17p deletion,t(4;14),and t(14;16)] in CD138(+) cells purified by magnetic cell sorting. RESULTS This test was validated with a low turnaround time and good reproducibility. Five of six samples showed genetic abnormalities. Monosomy/deletion 13 plus t(4;14) were found in two cases. CONCLUSION This technique together with magnetic cell sorting is effective and can be used in the routine laboratory practice. In addition,magnetic cell sorting provides a pure plasma cell population that allows other molecular and genomic studies. View Publication

产品类型：

产品号#：

产品名：
文献

Sun J et al. ( 2015) The Journal for Immunotherapy of Cancer 3 5

Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application

BACKGROUND: Virus-specific T-cells (VSTs) proliferate exponentially after adoptive transfer into hematopoietic stem cell transplant (HSCT) recipients,eliminate virus infections,then persist and provide long-term protection from viral disease. If VSTs behaved similarly when modified with tumor-specific chimeric antigen receptors (CARs),they should have potent anti-tumor activity. This theory was evaluated by Cruz et al. in a previous clinical trial with CD19.CAR-modified VSTs,but there was little apparent expansion of these cells in patients. In that study,VSTs were gene-modified on day 19 of culture and we hypothesized that by this time,sufficient T-cell differentiation may have occurred to limit the subsequent proliferative capacity of the transduced T-cells. To facilitate the clinical testing of this hypothesis in a project supported by the NHLBI-PACT mechanism,we developed and optimized a good manufacturing practices (GMP) compliant method for the early transduction of VSTs directed to Epstein-Barr virus (EBV),Adenovirus (AdV) and cytomegalovirus (CMV) using a CAR directed to the tumor-associated antigen disialoganglioside (GD2). RESULTS: Ad-CMVpp65-transduced EBV-LCLs effectively stimulated VSTs directed to all three viruses (triVSTs). Transduction efficiency on day three was increased in the presence of cytokines and high-speed centrifugation of retroviral supernatant onto retronectin-coated plates,so that under optimal conditions up to 88% of tetramer-positive VSTs expressed the GD2.CAR. The average transduction efficiency of early-and late transduced VSTs was 55 ± 4% and 22 ± 5% respectively,and early-transduced VSTs maintained higher frequencies of T cells with central memory or intermediate memory phenotypes. Early-transduced VSTs also had higher proliferative capacity and produced higher levels of TH1 cytokines IL-2,TNF-α,IFN-γ,MIP-1α,MIP-1β and other cytokines in vitro. CONCLUSIONS: We developed a rapid and GMP compliant method for the early transduction of multivirus-specific T-cells that allowed stable expression of high levels of a tumor directed CAR. Since a proportion of early-transduced CAR-VSTs had a central memory phenotype,they should expand and persist in vivo,simultaneously protecting against infection and targeting residual malignancy. This manufacturing strategy is currently under clinical investigation in patients receiving allogeneic HSCT for relapsed neuroblastoma and B-cell malignancies (NCT01460901 using a GD2.CAR and NCT00840853 using a CD19.CAR). View Publication

产品类型：

产品号#：

07811

07861

产品名：

Lymphoprep™

Lymphoprep™
产品手册
Tools for Your Immunology Research

产品类型：

品牌：

EasySep，ImmunoCult，RoboSep，RosetteSep，SepMate

产品号#：

07932

07933

07953

07949

07811

07861

10970

10990

10981

18063

17851

17851RF

17852

17852RF

17853

17853RF

17854

17854RF

17858

17858RF

17951

17951RF

17952

17952RF

17953

17953RF

产品名：

CryoStor®CS2

CryoStor®CS5

CryoStor®CS5

CryoStor®CS5

Lymphoprep™

Lymphoprep™

ImmunoCult™ 人CD3/CD28/CD2 T细胞激活剂

ImmunoCult™ 人CD3/CD28/CD2 T细胞激活剂

ImmunoCult™ XF 人T细胞扩增培养基，500 mL

EasySep™人CD4+CD127low CD25+调节性T细胞分选试剂盒

EasySep™人CD3正选试剂盒II

RoboSep™ 人CD3正选试剂盒II

EasySep™人CD4正选试剂盒II

RoboSep™ 人CD4正选试剂盒II

EasySep™人CD8正选试剂盒 II

RoboSep™ 人CD8正选试剂盒 II

EasySep™人CD19正选试剂盒II

RoboSep™ 人CD19正选试剂盒II

EasySep™人CD14正选试剂盒II

RoboSep™ 人CD14正选试剂盒II

EasySep™人T细胞分选试剂盒

RoboSep™ 人T细胞分选试剂盒

EasySep™人CD4+ T细胞分选试剂盒

RoboSep™ 人CD4+ T细胞分选试剂盒

EasySep™人CD8+ T细胞分选试剂盒

RoboSep™ 人CD8+ T细胞分选试剂盒
产品手册
Cell Separation Products for HLA Analysis

产品类型：

品牌：

EasySep，RoboSep，RosetteSep

产品号#：

07800

07850

15061HLA

15081HLA

15276

17854

17854RF

17855

17855RF

19655

19054HLA

19054HLARF

20104

20124

20125

21000

20119

20155

产品名：

氯化铵溶液

氯化铵溶液

RosetteSep™ HLA T细胞富集抗体混合物

RosetteSep™ HLA T细胞富集抗体混合物

RosetteSep™人脐带血祖细胞完全富集试剂盒

EasySep™人CD19正选试剂盒II

RoboSep™ 人CD19正选试剂盒II

EasySep™人CD56正选试剂盒 II

RoboSep™ 人CD56正选试剂盒 II

EasySep™ Direct人总淋巴细胞分选试剂盒

EasySep™ HLA B细胞富集试剂盒

RoboSep™ HLA B细胞富集试剂盒含滤芯吸头

RoboSep™ 缓冲液

RoboSep™ 缓冲液（5X浓缩液）

RoboSep™过滤头

RoboSep™- S

RoboSep™ 吸头组件抛光剂

RoboSep™分选试管套装（9个塑料管+吸头保护器）
技术公告
Fully Automated, High-Purity Cell Isolation for Chimerism Labs

产品类型：

细胞类型：

B 细胞，T 细胞，淋巴细胞，髓系细胞

产品号#：

21000

20119

20155

17881

17881RF

17884

17884RF

17875

17875RF

17871

17871RF

17874

17874RF

17885

17885RF

17878

17878RF

17876

17876RF

17882

17882RF

17886

17886RF

17888

17888RF

17889

17889RF

17873

17873RF

产品名：

RoboSep™- S

RoboSep™ 吸头组件抛光剂

RoboSep™分选试管套装（9个塑料管+吸头保护器）

EasySep™ HLA嵌合全血CD15正选试剂盒

RoboSep™ HLA嵌合全血CD15正选试剂盒

EasySep™ HLA嵌合全血髓系正选试剂盒

RoboSep™ HLA嵌合全血髓系正选试剂盒

EasySep™HLA嵌合白膜层（buffy coat）CD56 正选试剂盒

RoboSep™ HLA嵌合白膜层（buffy coat）CD56 正选试剂盒

EasySep™ HLA嵌合全血CD3正选试剂盒

RoboSep™ HLA嵌合全血CD3正选试剂盒

EasySep™ HLA嵌合全血CD19正选试剂盒

RoboSep™ HLA嵌合全血CD19正选试剂盒

EasySep™ HLA嵌合体全血CD33正选试剂盒

RoboSep™ HLA嵌合体全血CD33正选试剂盒

EasySep™ HLA嵌合白膜层CD14正选试剂盒

RoboSep™ HLA嵌合白膜层CD14正选试剂盒

EasySep™人CD33正选试剂盒II

RoboSep™ 人CD33正选试剂盒II

EasySep™ HLA嵌合全血CD66b正选试剂盒

RoboSep™ HLA嵌合全血CD66b正选试剂盒

EasySep™ HLA嵌合全血B细胞正选试剂盒

RoboSep™ HLA嵌合全血B细胞正选试剂盒

EasySep™ HLA嵌合全血CD4正选试剂盒

RoboSep™ HLA嵌合全血CD4正选试剂盒

EasySep™ HLA嵌合全血CD8正选试剂盒

RoboSep™ HLA嵌合全血CD8正选试剂盒

EasySep™ HLA嵌合全血淋巴细胞正选试剂盒

RoboSep™ HLA嵌合全血淋巴细胞正选试剂盒
26:43

线上讲座
Cell Separation Solutions for HLA and Chimerism Analysis

发布日期: 11/18/09
产品手册
Lymphoprep™ Density Gradient Medium for Mononuclear Cell Isolation

产品类型：

品牌：

Lymphoprep，SepMate

产品号#：

07811

07861

85415

85420

85450

85460

产品名：

Lymphoprep™

Lymphoprep™

SepMate™-15 (IVD), 100 units

SepMate™-15 (IVD)

SepMate™-50 (IVD)

SepMate™-50 (IVD)
56:02

线上讲座
Fully Automated Cell Separation for Chimerism Analysis with RoboSep™

发布日期: 2/8/11
产品手册
Fully Automated, High Purity Cell Isolation for Chimerism Labs

产品类型：

品牌：

EasySep，RoboSep，RosetteSep

产品号#：

17851

17851RF

17854

17854RF

17855

17855RF

17858

17858RF

产品名：

EasySep™人CD3正选试剂盒II

RoboSep™ 人CD3正选试剂盒II

EasySep™人CD19正选试剂盒II

RoboSep™ 人CD19正选试剂盒II

EasySep™人CD56正选试剂盒 II

RoboSep™ 人CD56正选试剂盒 II

EasySep™人CD14正选试剂盒II

RoboSep™ 人CD14正选试剂盒II
技术公告
Purity Assessment by Flow Cytometry for Lineage-Specific Chimerism Analysis

产品类型：

细胞类型：

B 细胞，NK 细胞，T 细胞，淋巴细胞，粒细胞及其亚群，造血干祖细胞，髓系细胞

产品号#：

21000

20119

20155

17881

17881RF

17884

17884RF

17875

17875RF

17871

17871RF

17874

17874RF

17885

17885RF

17878

17878RF

17876

17876RF

17882

17882RF

17886

17886RF

17888

17888RF

17889

17889RF

17873

17873RF

产品名：

RoboSep™- S

RoboSep™ 吸头组件抛光剂

RoboSep™分选试管套装（9个塑料管+吸头保护器）

EasySep™ HLA嵌合全血CD15正选试剂盒

RoboSep™ HLA嵌合全血CD15正选试剂盒

EasySep™ HLA嵌合全血髓系正选试剂盒

RoboSep™ HLA嵌合全血髓系正选试剂盒

EasySep™HLA嵌合白膜层（buffy coat）CD56 正选试剂盒

RoboSep™ HLA嵌合白膜层（buffy coat）CD56 正选试剂盒

EasySep™ HLA嵌合全血CD3正选试剂盒

RoboSep™ HLA嵌合全血CD3正选试剂盒

EasySep™ HLA嵌合全血CD19正选试剂盒

RoboSep™ HLA嵌合全血CD19正选试剂盒

EasySep™ HLA嵌合体全血CD33正选试剂盒

RoboSep™ HLA嵌合体全血CD33正选试剂盒

EasySep™ HLA嵌合白膜层CD14正选试剂盒

RoboSep™ HLA嵌合白膜层CD14正选试剂盒

EasySep™人CD33正选试剂盒II

RoboSep™ 人CD33正选试剂盒II

EasySep™ HLA嵌合全血CD66b正选试剂盒

RoboSep™ HLA嵌合全血CD66b正选试剂盒

EasySep™ HLA嵌合全血B细胞正选试剂盒

RoboSep™ HLA嵌合全血B细胞正选试剂盒

EasySep™ HLA嵌合全血CD4正选试剂盒

RoboSep™ HLA嵌合全血CD4正选试剂盒

EasySep™ HLA嵌合全血CD8正选试剂盒

RoboSep™ HLA嵌合全血CD8正选试剂盒

EasySep™ HLA嵌合全血淋巴细胞正选试剂盒

RoboSep™ HLA嵌合全血淋巴细胞正选试剂盒
科学海报
Fast and Easy Enrichment of Cell Subsets for HLA Analysis

产品类型：

Conference：

EFI 2012

产品号#：

85415

85420

85450

85460

产品名：

SepMate™-15 (IVD), 100 units

SepMate™-15 (IVD)

SepMate™-50 (IVD)

SepMate™-50 (IVD)
文献

Aljurf M et al. ( 2016) Biotechnology research international 2016 8589270

Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic Malignancies.

Background. We studied DNA chimerism in cell-free DNA (cfDNA) in patients treated with HSCT. Methods. Chimerism analysis was performed on CD3+ cells,polymorphonuclear (PMN) cells,and cfDNA using 16 small tandem repeat loci. The resulting labeled PCR-products were size-fractionated and quantified. Results. Analyzing samples from 191 patients treated with HSCT for nonneoplastic hematologic disorders demonstrated that the cfDNA chimerism is comparable to that seen in PMN cells. Analyzing leukemia patients (N = 126) showed that,of 84 patients with 100% donor DNA in PMN,16 (19%) had evidence of clinical relapse and textgreater10% recipient DNA in the plasma. Additional 16 patients of the 84 (19%) showed textgreater10% recipient DNA in plasma,but without evidence of relapse. Eight patients had mixed chimerism in granulocytes,lymphocytes,and plasma,but three of these patients had textgreater10% recipient DNA in plasma compared to PMN cells and these three patients had clinical evidence of relapse. The remaining 34 patients showed 100% donor DNA in both PMN and lymphocytes,but cfDNA showed various levels of chimerism. Of these patients 14 (41%) showed laboratory or clinical evidence of relapse and all had textgreater10% recipient DNA in cfDNA. Conclusion. Monitoring patients after HSCT using cfDNA might be more reliable than cellular DNA in predicting early relapse. View Publication

产品类型：

产品号#：

产品名：